↓ Skip to main content

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

Overview of attention for article published in Nature, August 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#31 of 49,021)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Readers on

mendeley
1029 Mendeley
citeulike
5 CiteULike
Title
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Published in
Nature, August 2016
DOI 10.1038/nature19323
Pubmed ID
Authors

Jeff Sevigny, Ping Chiao, Thierry Bussière, Paul H. Weinreb, Leslie Williams, Marcel Maier, Robert Dunstan, Stephen Salloway, Tianle Chen, Yan Ling, John O’Gorman, Fang Qian, Mahin Arastu, Mingwei Li, Sowmya Chollate, Melanie S. Brennan, Omar Quintero-Monzon, Robert H. Scannevin, H. Moore Arnold, Thomas Engber, Kenneth Rhodes, James Ferrero, Yaming Hang, Alvydas Mikulskis, Jan Grimm, Christoph Hock, Roger M. Nitsch, Alfred Sandrock, Sevigny, Jeff, Chiao, Ping, Bussière, Thierry, Weinreb, Paul H, Williams, Leslie, Maier, Marcel, Dunstan, Robert, Salloway, Stephen, Chen, Tianle, Ling, Yan, O'Gorman, John, Qian, Fang, Arastu, Mahin, Li, Mingwei, Chollate, Sowmya, Brennan, Melanie S, Quintero-Monzon, Omar, Scannevin, Robert H, Arnold, H Moore, Engber, Thomas, Rhodes, Kenneth, Ferrero, James, Hang, Yaming, Mikulskis, Alvydas, Grimm, Jan, Hock, Christoph, Nitsch, Roger M, Sandrock, Alfred

Abstract

Alzheimer's disease (AD) is characterized by deposition of amyloid-β (Aβ) plaques and neurofibrillary tangles in the brain, accompanied by synaptic dysfunction and neurodegeneration. Antibody-based immunotherapy against Aβ to trigger its clearance or mitigate its neurotoxicity has so far been unsuccessful. Here we report the generation of aducanumab, a human monoclonal antibody that selectively targets aggregated Aβ. In a transgenic mouse model of AD, aducanumab is shown to enter the brain, bind parenchymal Aβ, and reduce soluble and insoluble Aβ in a dose-dependent manner. In patients with prodromal or mild AD, one year of monthly intravenous infusions of aducanumab reduces brain Aβ in a dose- and time-dependent manner. This is accompanied by a slowing of clinical decline measured by Clinical Dementia Rating-Sum of Boxes and Mini Mental State Examination scores. The main safety and tolerability findings are amyloid-related imaging abnormalities. These results justify further development of aducanumab for the treatment of AD. Should the slowing of clinical decline be confirmed in ongoing phase 3 clinical trials, it would provide compelling support for the amyloid hypothesis.

Twitter Demographics

The data shown below were collected from the profiles of 1,282 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 1,029 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 19 2%
United Kingdom 12 1%
Spain 9 <1%
Germany 7 <1%
France 5 <1%
Brazil 4 <1%
Netherlands 4 <1%
Japan 4 <1%
Mexico 2 <1%
Other 13 1%
Unknown 950 92%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 254 25%
Researcher 230 22%
Student > Bachelor 163 16%
Student > Master 107 10%
Other 65 6%
Other 210 20%
Readers by discipline Count As %
Agricultural and Biological Sciences 269 26%
Medicine and Dentistry 189 18%
Neuroscience 167 16%
Biochemistry, Genetics and Molecular Biology 130 13%
Chemistry 66 6%
Other 208 20%

Attention Score in Context

This research output has an Altmetric Attention Score of 3013. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 November 2017.
All research outputs
#116
of 8,774,866 outputs
Outputs from Nature
#31
of 49,021 outputs
Outputs of similar age
#5
of 254,558 outputs
Outputs of similar age from Nature
#2
of 983 outputs
Altmetric has tracked 8,774,866 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 49,021 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 76.1. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 254,558 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 983 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.